Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06304168 · ClinicalTrials.gov registry record
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 6,150
- Enrollment target
- 1
- Study location
NCT06304168: Recruiting study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Mayo Clinic.
NCT06304168 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 6,150 participants, above the 1,106-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (456% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06304168, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 6,150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the potential value of a new blood test approach for early detection of cancer.
Primary Outcome
Blood samples will be assayed for known cancer markers to explore the potential value of a new blood test approach to detecting cancer. Accuracy of results may be evaluated based on review of past, present, and future medical record information.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,150 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2028-05-15 |
What NCT06304168 shows while recruiting
NCT06304168 is an observational study that tracks outcomes without assigning an intervention. Its 6,150 participants enrollment target places it among the larger protocols in the corpus, above the 1,106-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (456% higher).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06304168 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06304168 about?
NCT06304168 is a clinical study titled "Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study". This study explores the potential value of a new blood test approach for early detection of cancer.
What is the current status of trial NCT06304168?
This trial is currently recruiting. The enrollment target is 6,150 participants. The study started on 2019-05-13. Estimated completion is 2028-05-15.
What conditions does trial NCT06304168 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.
What interventions are being tested in trial NCT06304168?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06304168?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06304168 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06304168's enrollment target sits among peer trials
6,150 7th of 176 higher than 170 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT07049861 · 6,200 participants · NA
Advancing Biopsychosocial Care Training Initiative
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT03960099 · 6,250 participants · NA
Pictographs for Preventing Wrong-Patient Errors in NICUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI